Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CGI
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease LHGDN Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. 12917419 2003
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Furthermore, we found that melanoma cell integrin alphav was required for MAPK kinase (MEK) 1 and extracellular signal-regulated kinase (ERK)1/2 activity in 3D-collagen, whereas inhibition of MEK1 activity induced apoptosis. 15557124 2004
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease LHGDN Surprisingly, MEK1 and ERK1/2 activities were restored in integrin alphav-negative melanoma cells by suppression of p53, whereas concomitant block of MEK1 induced apoptosis. 15557124 2004
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease BEFREE Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. 16170021 2005
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Consistent with these observations, pharmacological inhibition of BRAF(V600E) or MEK1/2 in human melanoma cells (using PLX4720 and CI-1040 respectively) led to a striking elevation of BIM expression. 18715233 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE FABP7 mRNA and protein level is down-regulated following treatment of melanoma cell lines with a PKC activator (PMA) or MEK1 inhibitor (PD98059). 18826602 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE We thus report for the first time a low prevalence of MEK1 mutations in melanoma and colon cancer. 19411838 2009
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease CLINVAR MEK1 mutations confer resistance to MEK and B-RAF inhibition. 19915144 2009
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR MEK1 mutations confer resistance to MEK and B-RAF inhibition. 19915144 2009
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE One such mutation, MEK1(P124L), was identified in a resistant metastatic focus that emerged in a melanoma patient treated with AZD6244. 19915144 2009
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 21107320 2010
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. 21383288 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. 22048237 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. 22197931 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease CTD_human Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. 22197931 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. 22197931 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE New, highly selective inhibitors of BRAF and MEK1/2 have shown promise in clinical trials, including in previously intractable diseases such as melanoma. 22562245 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. 22588879 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma. 22588879 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Melanoma genome sequencing reveals frequent PREX2 mutations. 22622578 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma. 23248257 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease CLINVAR Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. 23444215 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304 2013